Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  ERYTECH Pharma    ERYP   FR0011471135

ERYTECH PHARMA

(ERYP)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
8.15(c) 8.07(c) 8.59(c) 8.62(c) 8.88(c) Last
203 706 171 432 251 947 160 388 322 338 Volume
+3.43% -0.98% +6.44% +0.35% +3.02% Change
More quotes
Financials
Sales 2020 7,69 M 9,28 M 9,28 M
Net income 2020 -63,7 M -76,9 M -76,9 M
Net cash position 2020 3,60 M 4,35 M 4,35 M
P/E ratio 2020 -2,70x
Yield 2020 -
Sales 2021 6,17 M 7,44 M 7,44 M
Net income 2021 -48,3 M -58,3 M -58,3 M
Net Debt 2021 33,4 M 40,3 M 40,3 M
P/E ratio 2021 -4,27x
Yield 2021 -
Capitalization 178 M 215 M 215 M
EV / Sales 2020 22,7x
EV / Sales 2021 34,3x
Nbr of Employees 206
Free-Float 99,3%
More Financials
Company
VERYTECH Pharma is a biopharmaceutical company in the clinical stage that develops innovative therapies based on red blood cells to fight cancers and orphan diseases. Leveraging its proprietary ERYCAPS® platform, a new technology for encapsulating drugs in red blood cells, ERYTECH Pharma is developing a portfolio of product candidates targeting markets with significant unmet medical needs. eryaspase, the company's... 
More about the company
Notations Surperformance© of ERYTECH Pharma
Trading Rating : Investor Rating :
More Ratings
All news about ERYTECH PHARMA
01/15ERYTECH PHARMA S A : Doses First Patient in Phase 1 Trial of Pancreatic Cancer
MT
01/15European ADRs Move Sharply Lower in Friday Trading
MT
01/14ERYTECH PHARMA S A : Enrolls First Patient in Phase 1 Trial of Pancreatic Cancer..
MT
01/08European ADRs Nudge Higher in Friday Trading
MT
01/06ERYTECH PHARMA : to Present at the H.C. Wainwright Virtual BioConnect 2021 Confe..
GL
01/06European ADRs Climb Sharply Higher in Wednesday Trading
MT
01/04ERYTECH PHARMA : to Present at the LifeSci Partners 10th Annual Healthcare Corpo..
GL
2020European ADRs Move Lower in Thursday Trading
MT
2020ERYTECH PHARMA : Monthly statement on outstanding equity shares and voting right..
CO
2020European ADRs Move Higher in Wednesday Trading
MT
2020European ADRs Move Higher in Tuesday Trading
MT
2020European ADRs Climb Higher in Wednesday Trading
MT
2020European ADRs Tumble Lower in Monday Trading
MT
2020European ADRs Move Lower in Friday Trading
MT
2020ERYTECH PHARMA : Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line ..
AQ
More news
News in other languages on ERYTECH PHARMA
01/15Washington, morne plaine
01/15EN DIRECT DES MARCHES : Carrefour, Bouygues, Valeo, Nanobiotix, DBV, SAP, Goldma..
01/14ERYTECH PHARMA : annonce le recrutement du premier patient dans une étude de pha..
01/07EN DIRECT DES MARCHES : Saint-Gobain, Dassault, Pierre & Vacances, SMCP, DBV, La..
01/07Jusqu'à la lie
More news
Chart ERYTECH PHARMA
Duration : Period :
ERYTECH Pharma Technical Analysis Chart | ERYP | FR0011471135 | MarketScreener
Technical analysis trends ERYTECH PHARMA
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 22,80 €
Last Close Price 8,88 €
Spread / Highest target 188%
Spread / Average Target 157%
Spread / Lowest Target 125%
EPS Revisions
Managers and Directors
NameTitle
Gil Beyen Chief Executive Officer & Director
Jean-Paul Kress Chairman
Eric Soyer Chief Operating & Financial Officer
Iman El-Hariry Chief Medical Officer
Stewart Craig Chief Technical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ERYTECH PHARMA24.89%215
GILEAD SCIENCES, INC.8.70%79 386
VERTEX PHARMACEUTICALS-4.57%58 652
REGENERON PHARMACEUTICALS7.21%54 665
WUXI APPTEC CO., LTD.3.52%52 469
BEIGENE, LTD.33.52%31 458